Tag Archive for: Strasbourg

Kainova Therapeutics Expands Phase I/II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe

/in

First patient dosed in France, expanding the DOMISOL study beyond Australia DT‑7012 is being evaluated as monotherapy and in combination with pembrolizumab in a global clinical development program Montreal, Canada – Strasbourg, France – Boston, United States, April 9, 2026: Kainova Therapeutics (“the Company”), a key player for breakthrough treatments in immuno-oncology and inflammation, today […]

Read more

Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors

/in

Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activity Reinforce EP4 receptor antagonism as a validated, high-value strategy to overcome immunotherapy resistance Montreal, Canada – Strasbourg, France – Boston, United States, March 10, 2026: Kainova Therapeutics (“the Company”), a key player for breakthrough treatments in immuno-oncology and inflammation, today […]

Read more
© Optimum Strategic Communications.